One of the reasons Endur-Acin® ER has maintained a loyal following among practitioners for decades is that its clinical research has consistently demonstrated unusually low flushing-related discontinuation rates.
Results from multiple clinical trials indicate that Endur-Acin® ER is associated with dropout rates of about 4–5% on average from minor side effects such as flushing, itching, and digestive upset, using typical dosages of 1–2 g/day, thanks to its unique SmartMatrix™ wax-matrix delivery system. This means users experience substantially higher compliance than many practitioners expect when using nicotinic acid to support heart health and blood lipid balance.*
The reason is simple: successful niacin therapy depends on both formulation and patient education.
Rather than delivering a rapid surge of nicotinic acid, Endur-Acin® ER uses SmartMatrix™ delivery to gradually releases niacin over approximately 6–8 hours. This controlled delivery helps reduce the intensity of prostaglandin-mediated flushing while allowing patients time to adapt to increasing doses. Combined with a structured titration schedule, this approach can significantly improve long-term compliance.
The Three Keys to Niacin Tolerability
Practitioners who achieve the greatest success with niacin typically focus on three areas:
1. Gradual Dose Escalation
Patients should be allowed to adapt slowly to nicotinic acid exposure. The Endur-Acin® ER protocol begins with 250 mg twice daily, progresses to 500 mg twice daily, and ultimately reaches 750 mg twice daily over several weeks. This gradual increase helps reduce flushing and improves patient confidence in the protocol.
2. Strategic Flushing Reduction
Although flushing is generally harmless and often decreases over time, it can be alarming to new users. Practitioners can help patients minimize flushing by:
- Taking Endur-Acin® ER with food
- Drinking adequate water with each dose
- Avoiding hot beverages immediately after dosing
- Avoiding vigorous exercise shortly after dosing
These simple measures often make the difference between a patient continuing therapy or abandoning it after the first few doses.
3. Respecting Hepatic Metabolism
One of the most overlooked aspects of niacin therapy is dosing frequency.
Nicotinic acid is metabolized through several pathways in the liver. When extended-release niacin is dosed too closely together, metabolic pathways may become saturated, increasing reliance on secondary pathways that have historically been associated with elevations in liver enzymes.
For this reason, we recommend spacing doses approximately 12 hours apart whenever possible. A morning dose and an evening dose provide time for normal metabolic processing while maintaining consistent nutrient exposure. This schedule aligns with the SmartMatrix™ extended-release design and helps support long-term tolerability.
Patients should also be encouraged to:
- Avoid excessive alcohol intake
- Maintain adequate hydration
- Consume foods rich in methyl-donor nutrients such as folate, choline, betaine, and methionine
- Follow periodic laboratory monitoring as recommended by their healthcare provider
These strategies help support normal niacin metabolism and responsible long-term use.
A Better Patient Experience Leads to Better Compliance
The ultimate goal of any titration protocol is not simply reaching a target dose—it is helping patients remain on therapy long enough to realize its benefits.
By combining SmartMatrix™ extended-release technology, gradual titration, proper 12-hour dosing intervals, and practical flushing-reduction strategies, Endur-Acin® ER offers practitioners a clinically proven approach to improving niacin tolerability. The low dropout rates observed in clinical studies serve as a reminder that when niacin is introduced thoughtfully, most patients can successfully adapt and remain compliant long term.*
Related:
A New Look at Nutrient Delivery: Why SmartMatrix™ Tablet Technology Is Changing the Conversation
References
Alderman JD, Pasternak RC, Sacks FM, Smith HS, Monrad ES, Grossman W. Effect of a modified, well-tolerated niacin regimen on serum total cholesterol, high density lipoprotein cholesterol and the cholesterol to high density lipoprotein ratio. Am J Cardiol. 1989;64(12):725-729. doi:10.1016/0002-9149(89)90754-6
Aronov DM, Keenan JM, Akhmedzhanov NM, Perova NV, Oganov RY, Kiseleva NY. Clinical trial of wax-matrix sustained-release niacin in a Russian population with hypercholesterolemia. Arch Fam Med. 1996;5(10):567-575. doi:10.1001/archfami.5.10.567
Dunatchik AP, Ito MK, Dujovne CA. A systematic review on evidence of the effectiveness and safety of a wax-matrix niacin formulation. J Clin Lipidol. 2012;6(2):121-131. doi:10.1016/j.jacl.2011.07.003
Keenan JM, Bae CY, Fontaine PL, et al. Treatment of hypercholesterolemia: comparison of younger versus older patients using wax-matrix sustained-release niacin. J Am Geriatr Soc. 1992;40(1):12-18. doi:10.1111/j.1532-5415.1992.tb01822.x
Keenan JM, Fontaine PL, Wenz JB, Myers S, Huang ZQ, Ripsin CM. Niacin revisited. A randomized, controlled trial of wax-matrix sustained-release niacin in hypercholesterolemia. Arch Intern Med. 1991;151(7):1424-1432. doi:10.1001/archinte.151.7.1424
Keenan JM, Wenz JB, Ripsin CM, Huang Z, McCaffrey DJ. A clinical trial of oat bran and niacin in the treatment of hyperlipidemia. J Fam Pract. 1992;34(3):313-319.
Keenan JM. Wax-matrix extended-release niacin vs inositol hexanicotinate: a comparison of wax-matrix, extended-release niacin to inositol hexanicotinate “no-flush” niacin in persons with mild to moderate dyslipidemia. J Clin Lipidol. 2013;7(1):14-23. doi:10.1016/j.jacl.2012.10.004
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease.
SmartMatrix is a trademark of Innovite, Inc.
